Santen, Inc.
About Santen, Inc.
Santen is a global pharmaceutical and medical device company focused solely on ophthalmology. We’re committed to serving serious unmet needs by developing innovative solutions that protect vision and, in turn, preserve quality of life for people around the world.
Santen USA, located in Emeryville, CA, is an important part of our ophthalmic research, development, and commercialization efforts worldwide and the home of our regional business teams. By leveraging our deep industry knowledge and a network of external partners, we aim to deliver game-changing therapies and make hope a reality for people facing vision impairment and loss.
Our deep roots start in Japan, Santen’s worldwide headquarters, where the company began in 1890. Since then, Santen has become an established leader in the Asian and European prescription ophthalmology marketplaces and continues to expand across global markets, including the United States. Today, Santen employs more than 4,000 people worldwide and sells specialty ophthalmic products in more than 60 countries.
With a clear focus on vision, we aim to deliver the highest quality products, to act with integrity, to earn the trust of our partners and customers, and to deliver sight-saving innovations to physicians and patients who are waiting for them.
37 articles with Santen, Inc.
-
Santen and UBE Received FDA Approval for OMLONTI® (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
9/26/2022
Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), and UBE Corporation (UBE) today announced that the U.S. Food and Drug Administration (FDA) has approved OMLONTI® (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension.
-
Santen’s Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States
5/2/2022
Santen’s Verkazia ® (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States.
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions
12/7/2021
Aerie Pharmaceuticals, Inc. announced that Aerie and Santen have entered into an exclusive development and commercialization agreement for Rhopressa®/Rhokiinsa® 0.02% and Rocklatan®/Roclanda® 0.02%/0.005%.
-
Global biopharmaceutical firms Santen SA and Sydnexis have entered an exclusive licensing deal for a drug formulation that aims to treat progressive myopia.
-
Santen Receives FDA Approval for Verkazia™ (Cyclosporine Ophthalmic Emulsion) 0.1% for the Treatment of Vernal Keratoconjunctivitis in Children and Adults
6/24/2021
Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd., a global company focused exclusively on eye care, announced that the U.S. Food and Drug Administration has approved Verkazia™ 0.1% eye drops for the treatment of vernal keratoconjunctivitis in children and adults.
-
The U.S. FDA has had a mix of announcements this week, from drug approvals to the acceptance of NDAs and INDs. Here’s a look.
-
Santen Announces Health Canada Approval of PRESERFLO MicroShunt
5/4/2021
Santen Canada Inc., a subsidiary of Santen Pharmaceutical Co., Ltd., a global company focused exclusively on ophthalmology, announced the approval of PRESERFLOTM MicroShunt by Health Canada.
-
Santen Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for Cyclosporine Topical Ophthalmic Emulsion, 0.1% for the Treatment of Severe Vernal Keratoconjunctivitis in Patients Ages 4-18
10/26/2020
Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (hereinafter, Santen), a global company focused exclusively on ophthalmology, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for cyclosporine topical ophthalmic emulsion, 0.1% for the treatment of se
-
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
-
Santen Inc. Announces Appointment of Tatsuya Kaihara as Corporate Officer and Head of North America Business of Santen Pharmaceutical
4/1/2020
Santen Inc., a U.S. subsidiary of Santen Pharmaceutical Co., Ltd., a global company focused exclusively on ophthalmology, today announced the appointment of Tatsuya Kaihara as Corporate Officer and Head of North America Business of Santen Pharmaceutical.
-
Santen and TRACON Discontinue Development of DE-122 for Wet Age-Related Macular Degeneration
3/9/2020
Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; hereinafter, “Santen”) and TRACON Pharmaceuticals, Inc. (Head Office: San Diego, CA; hereinafter, “TRACON”) today announced the discontinuation of the development of DE-122 for the treatment of wet age-related macular degeneration (wAMD) following the review of recently obtained top-line data from the Phase 2a AVANTE clinical study. The Phase 2a AVANTE clinical study is a rando
-
Santen to Conduct Activities to Raise Awareness on Importance of Early Detection and Treatment of Glaucoma during World Glaucoma Week (March 8-14, 2020)
3/5/2020
Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; Chairman and CEO: Akira Kurokawa; hereinafter, “Santen”) announced today that it will support glaucoma awareness-raising activities to be conducted around the world from March 8 to 14, 2020.
-
Santen and Verily Establish Joint Venture to Develop and Commercialize Unique Ophthalmic Devices
2/4/2020
Santen Pharmaceutical Co., Ltd. (Head office: Osaka, hereinafter “Santen”) and Verily, an Alphabet company, announced the establishment of a joint venture※ focused on applying microelectronics and scalable digital technologies to ophthalmology.
-
Santen Announces Topline Pivotal Data for DE-128 (MicroShunt) Demonstrating Reductions in Intraocular Pressure and Medication Use in Patients with Mild, Moderate and Severe Primary Open-Angle Glaucoma
8/30/2019
Santen Pharmaceutical Co., Ltd. (“Santen” TSE: 4536) today announced the results of INN-005, a prospective, randomized, controlled, single-masked, multicenter study to assess the safety and effectiveness of DE-128 (MicroShunt) standalone, without concomitant cataract extraction.
-
Santen Hosts Event to Raise Public Awareness of Importance of Continued Glaucoma Treatment Prior to Sponsoring World Glaucoma Week in March
1/30/2019
As part of its efforts to raise public awareness of glaucoma, Santen Pharmaceutical Co., Ltd., based in Osaka, will sponsor glaucoma awareness-raising activities to be conducted around the world during the World Glaucoma Week, from Sunday, March 10, to Saturday, March 16, 2019.
-
Santen Expands Research and Development Leadership Team with Additions of Reza M. Haque, MD, PhD and Peter Sallstig, MD, MBA
11/15/2018
Reza M. Haque, MD, PhD, has been appointed as Senior Vice President, Global Research and Development Strategy, and Peter Sallstig, MD, MBA, has been appointed as Senior Vice President, Global Product Development.
-
BioSpace Movers and Shakers Nov. 5
11/5/2018
Biopharma companies make key appointments to fill leadership positions. Let's take a look! -
Santen Announces Initiation of Phase 3 Clinical Development Program (SPECTRUM) in the United States Evaluating Omidenepag Isopropyl (DE-117) for the Treatment of Glaucoma or Ocular Hypertension
10/22/2018
Pivotal Phase 3 development program (SPECTRUM) in the United States, evaluating the investigational use of omidenepag isopropyl (DE-117), a selective agonist for the prostanoid receptor EP2, for the treatment of glaucoma or ocular hypertension (OHT).
-
Santen Presents Phase I/II Data on DE-122 (Carotuximab) in Patients With Refractory Wet Age-Related Macular Degeneration
2/12/2018
No serious adverse events were reported.